

Author Relationships With Industry and Other Entities (Comprehensive)—ACC/AHA/HHS Strategies to Enhance Application of Clinical Practice Guidelines in Patients With Cardiovascular Disease and Comorbid Conditions (March 2014)

Committee Member	Employment	Consultant	Speaker's Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Donna K. Arnett (Past President, AHA)	University of Alabama School of Public Health, Department of Epidemiology—Professor and Chair	None	None	None	None	None	None
Jeffrey L. Anderson (ACC/AHA Task Force on Practice Guidelines)	Intermountain Heart Institute, Intermountain Healthcare—Associate Chief of Cardiology	<ul style="list-style-type: none"> • The Medicines Company • Sanofi-aventis 	None	None	<ul style="list-style-type: none"> • Academic Research Group (DSMB) • Harvard (DSMB) • ICON Clinical Research (DSMB) • NIH† 	• NIH†	None
Richard A. Goodman (HHS)	U.S. Department of Health and Human Services, Office of the Assistant Secretary for Health, and the National Center for Chronic Disease Prevention and Health Promotion, Center for Disease Control and Prevention	None	None	None	None	None	None
Jonathan L. Halperin (ACC/AHA Task Force on Practice Guidelines)	The Cardiovascular Institute, Mount Sinai Medical Center, Division of Cardiology—Professor of Medicine	<ul style="list-style-type: none"> • AstraZeneca • Bayer • Biotronik* • Boehringer Ingelheim* • Boston Scientific • Bristol-Myers Squibb • Daiichi-Sankyo • Janssen Pharmaceuticals • Johnson & Johnson • Medtronic • Pfizer • Sanofi-aventis 	None	None	None	None	None

Anand K. Parekh (HHS)	U.S. Department of Health and Human Services—Deputy Assistant Secretary for Health (Science and Medicine)	None	None	None	None	None	None
William A. Zoghbi (Past President, ACC)	Methodist DeBakey Heart and Vascular Center—William L. Winters Chair of Cardiovascular Imaging; The Methodist Hospital—Director, Cardiovascular Imaging	None	None	• GE Healthcare*	None	None	None

This table represents all relationships of committee members with industry and other entities that were reported by authors, including those not deemed to be relevant to this document, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of $\geq 5\%$ of the voting stock or share of the business entity, or ownership of $\geq \$10,000$ of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to <http://www.cardiosource.org/Science-And-Quality/Practice-Guidelines-and-Quality-Standards/Relationships-With-Industry-Policy.aspx> for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees.

*Significant relationship.
 †No Financial Benefit.

ACC indicates American College of Cardiology; AHA, American Heart Association; DSMB, data safety monitoring board; and HHS, U.S. Department of Health and Human Services.